Die tumorassoziierte Proteolyse beim Ovarialkarzinom

Zusammenfassung

Im Rahmen einer prospektiven Studie wurde die Bedeutung der tumorassoziierten Proteolyse beim fortgeschrittenen Ovarialkarzinom FIGO III untersucht. Der Plasminogenaktivator vom Urokinase-Typ (u-PA) und dessen Inhibitor, der Plasminogenaktivator-Inhibitor (PAI-1), wurden im Gewebe von benignen und malignen Ovarialtumoren gemessen. Für beide Faktoren konnten Schwellenwerte berechnet werden, nach denen die Patientinnen mit Ovarialkarzinom FIGO III in Risikogruppen unterteilt werden konnten: Patientinnen mit niedrigem u-PA (<0,9 ng/mg Protein) und niedrigem PAI-1 (<13,5 ng/mg Protein) hatten eine statistisch signifikant bessere Prognose als Patientinnen mit hohen u-PA- und/oder hohen PAI-1-Werten. In der Multivarianz-Analyse erwiesen sich u-PA und PAI-1 bezüglich ihrer prognostischen Wertigkeit für das Überleben der Patientinnen nach dem Parameter Resttumor als zweitstärkste Prognosefaktoren und waren den anderen klinischen Faktoren wie Alter, Nodalstatus, präoperative Aszitesmenge und präoperativer Tumormarker deutlich überlegen. Aus diesen Daten kann gefolgert werden, daß u-PA und PAI-1 zuverlässige tumorbiologische Parameter darstellen, die Wachstumsverhalten, Differenzierung und Aggressivität eines Tumors näher beschreiben können.

Schlüsselwörter

Ovarialkarzinom - Proteolyse - u-PA - PAI-1 - Prognose

• LITERATUR

• 1 Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator releasd in tissue culture. Nature 1976; 261: 595-7.
• 2 Bauknecht T, Runge M, Schwall M, Pfleiderer A. Occurence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 1988; 29: 147-57.
• 3 Berchuck A, Rodriguez GC, Kamel A. et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991; 164: 669-74.
• 4 Berdel WE, Wilhelm O, Schmitt M. et al. Urokinase-type plasminogen activator (u-PA), a protease with cytokine-like activity in human HL-60 leukemic cell line. Int J Oncol 1993; 03: 607-13.
• 5 Berns EMJJ, Klijn JGM, Schmitt M. et al. Occurence and interrelationships of urokinase-type plasminogen activator, plasminogen activator inhibitor I and cathepsin D in human ovarian tissues. (Submitted to AACR 1994).
• 6 Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203-9.
• 7 Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. Fibrinolysis 1990; 07 (Suppl. 01) 17-8.
• 8 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 02: 73-84.
• 9 Burghardt E, Lahousen M, Stettner H. Die operative Behandlung des Ovarialkarzinoms. Geburtsh Frauenheilk 1990; 50: 670-7.
• 10 Burtin P, Chavanel G, André J. The plasmin system in human colonic tumors: an immunofluorescence study. Int J Cancer 1985; 35: 307-14.
• 11 Casslén B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994; 30A: 1302-11.
• 12 Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972; 34: 187-220.
• 13 Dano K, Andreasen PA, Grondahl-Hansen J. et al. Plasminogen activators, tissue degradation and cancer. Adv Cancer RES 1985; 44: 139-266.
• 14 Dembo AJ, Davy M, Stenwig AE. et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-73.
• 15 Duffy MJ. Urokinase-type plasminogen activator and malignancy. Fibrinolysis 1990; 07: 295-302.
• 16 Friedlander ML, Quinn MA, Fortune D. et al. The relationship of steroid receptor expression to nuclear DNA distribution and clinicopathological characteristics in epithelial ovarian tumors. Gynecol Oncol 1989; 32: 184-90.
• 17 Gajewski WH, Fuller AF, Pastel-Ley C. et al. Prognostic significance of DNA content in epithelial ovarian cancer. Gynecol Oncol 1994; 53: 5-12.
• 18 Graeff H, Harbeck N, Pache L. et al. Prognostic impact and clinical relevance of tumor- associated proteases in breast cancer. Fibrinolysis 1992; 06 (Suppl. 04) 45-53.
• 19 Griffiths CT, Parker LM, Fuller Jr AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979; 63: 235-40.
• 20 Hacker NF, Berek JS, Lagasse LD. et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-20.
• 21 Hearing V, Law L, Corti A. et al. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 1988; 48: 1270-8.
• 22 Heintz APM, Hacker NF, Berek JS. et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986; 67: 783-8.
• 23 Jänicke F, Hölscher M, Kuhn M. et al Schlüsselwörter. Radical surgical procedure improves survival time in patients with recurrent ovarian cancerCancer 1992; 70: 2129-36.
• 24 Jänicke F, Schmitt M, Pache L. et al. Urokinase (u-PA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
• 25 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
• 26 Kobayashi H, Schmitt M, Goretzki L. et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-u-PA). J Biol Chem 1991; 26: 5147-52.
• 27 Kobayashi H, Ohi H, Hinohara H. et al. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 1993; 67: 537-44.
• 28 Kaern J, Tropé CG, Kristensen GB, Pettersen EO. Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 1994; 73: 1870-7.
• 29 Kühnle H, Hilfrich J. Chemotherapie des fortgeschrittenen Ovarialkarzinoms. Onkologie 1985; 08: 374-82.
• 30 Kuhn W, Jänicke F, Pache L. et al. Entwicklungen in der Theapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtsh Frauenheilk. 193; 53. 293-302.
• 31 Kuhn W, Pache L, Schmalfeldt B. et al. Urokinase (u-PA) und PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum- based chemotherapy. Gynecol Oncol. 1994 (in press).
• 32 Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Cancer 1992; 69: 2668-75.
• 33 Leake RE, Owens O. The prognostic value of steroid receptors, growth factors and growth factor receptors in ovarian cancer. In: Ovarian Cancer. Biological and Therapeutic Challenges. Sharp F, Mason WP, Leake RE. (eds). Cambridge: Chapman & Hall; 1990: 69-75.
• 34 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
• 35 Moser TI, Young TN, Rodriguez GC. et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56: 552-9.
• 36 Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors u-PA and PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343: 117.
• 37 Oh D, Hwang SG, Hong SY. et al. Fibrinolytic changes in malignant ascites. Fibrinolysis 1994; 08: 156-61.
• 38 Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-9.
• 39 Ossowski L, Zelent A, Kook YH. Antisense inhibition of urokinase receptor in human carcinoma: Biological effects. Abstract 19 at Molecular & Cellular Biology of Plasminogen Activation. Cold Spring Harbor Lab; New York: 1993
• 40 Pedersen H, Grondahl-Hansen J, Francis D. et al. Urokinase and plasminogen activator inhibitor type I in pulmonary adenocarcinoma. Cancer Res 1994; 54: 120-3.
• 41 Pfleiderer A. Malignome des Ovars. In: Klinik der Frauenheilkunde und Geburtshilfe. Wulf K-H, Schmidt-Matthiesen H. (Hrsg). München: Urban & Schwarzenberg; 1989. Bd. 12..
• 42 Pickel H, Lahousen M, Grardi F. et al. Intraperitoneal and retroperitoneal spread of ovarian cancer. In: Ovarian Cancer. Biological and Therapeutic Challenges. Sharp F, Mason WPP, Leake RE. (eds). Cambridge: Chapman and Hall; 1990: 171-8.
• 43 Pujade-Lauraine E, Lu H, Mirshahi S. et al. The plasminogen-activation system in ovarian tumors. Int J Cancer 1993; 55: 27-31.
• 44 Röbl M, Jürgensmeyer K, Hafter R. et al. Relation of fibrin and tumor-associated antigens to the spread of ovarian cancer. Fibrinolysis 1987; 01: 143-8.
• 45 Schlechte W, Murano G, Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 1989; 49: 6064-9.
• 46 Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 06 (Suppl. 04) 3-26.
• 47 Schmitt M, Jänicke F, Thomssen C. et al. Clinical relevance of the plasminogen activator system in tumor invasion and metastasis in breast cancer. Excerpta Medica 1993; 1042: 331-41.
• 48 Schmitt M, Wilhelm O, Jänicke F. et al. Urokinase-type plasminogen activator (u-PA) and its receptor (CD87). A new target in tumor invasion and metastasis. Berlin: Springer.;
• 49 Slotman BJ, Kühnei R, Ramanath BRao. et al. Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival. Gynecol Oncol 1989; 33: 76-81.
• 50 Thigpen J, Blessin JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol 1989; 06 (04) (Suppl. 06) 58-65.
• 51 Tyson FL, Boyer CM, Kaufmann R. et al. Expression and amplification of the HER- 2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 1991; 165: 640-6.
• 52 Ulm K, Schmoor C, Sauerbrei W. et al. Strategien zur Auswertung einer Therapiestudie mit der Überlebenszeit als Zielkriterium. Biometrie u. Informatik in Medizin u. Biologie 1989; 04: 71-2.
• 53 Wilhelm O, Hafter R, Coppenrath E. et al. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res 1988; 48: 3507-14.
• 54 Wilhelm O, Hafter R, Henschen A. et al. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990; 75: 1673-8.
• 55 Wilhelm O, Weidle U, Höhl S. et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (u-PA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Letter 1994; 337: 131-4.
• 56 Wilhelm O, Reuning U, Jänicke F. et al. The role of proteases in tumor invasion and metastasis: Prognostic impact and therapeutical challenge?. Onkologie 1994; 17: 358-66.
• 57 Wu PC, Lang JH, Huang RL. et al. Lymphnode metastasis and retroperitoneal lymphadenectomy in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989; 03 (01) 143-55.
• 58 Young TN, Rodriguez GC, Moser TL. et al. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 1994; 170: 1285-96.